Результаты поиска

Individuals with Restless Legs Syndrome Tend to have Severe Depressive Symptoms: Findings from a Community-Based Cohort Study.

Restless legs syndrome (RLS) is a sensorimotor neurological disturbance causing physical and psychological distress. Here, we investigated the severity and effect of depressive symptoms in RLS among a Korean cohort population. Depressive symptoms were more prevalent in the RLS group than in the non-RLS group [≥mild depression: odds ratio (OR)=1.95, p<0.001; ≥ moderate depression: OR=6.15, p<0.001; and ≥severe depression: OR=56.54, p<0.001], with a predominant proportion of severe depression (97%) in the RLS group. We found that difficulty falling asleep (OR=8.16, p<0.001), broken sleep (OR=11.

Совпадение в полном тексте источника
… When treating patients with RLS comorbid with depression, the RLS symptoms should be closely monitored because antidepressant medications could aggravate the RLS symptoms, 48 49 50 and the clinicians should consider the prescription of dopamine agonists such as pramipexole for control of RLS symptoms … Medications associated with restless legs syndrome: a case-control study in the US Renal Data System (USRDS) Sleep Med 2014 15 1241 1245 25156752 10.1016/j.sleep.2014.05.011 PMC4172448 51 Makiguchi A Nishida M Shioda K Suda S Nisijima K Kato S Mirtazapine-induced restless legs syndrome treated with pramipexole …

Treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine clinical practice guideline.

INTRODUCTION: This guideline establishes clinical practice recommendations for treatment of restless legs syndrome (RLS) and periodic limb m … y augmentation). UNLABELLED: 12. In adults with RLS, the AASM suggests against the standard use of pramipexole (conditional recommendation, moderate certainty of evidence). UNLABELLED: Remarks: pramipexole may be used to treat RLS in patients who place a higher value on the reduction of restless legs symptoms with short-term use and a lower value on adverse …

Сексуальная дисфункция при расстройствах движения: распространенность, клинические особенности, связанные с этим факторы и управление.

Сексуальная дисфункция является распространенным, но недостаточно изученным симптомом немоторного расстройства движения. В то время как болезнь Паркинсона (PD) чаще всего исследуется, сексуальная дисфункция также отмечается в болезни Хантингтона, диспропорции и других расстройствах движения. Клинические представления являются разнородными и включают в себя сокращение желания, эректильную дисфункцию, эякуляционные и оргазмические расстройства, трудности с смазкой, диспаревинию и гиперсексуальность. В ДИ оценки распространенности заболеваний в различных исследованиях сильно различаются, главным

Совпадение в полном тексте источника
… At the individual level, a case report described hypersexuality emerging within one month of pramipexole initiation and remitting completely after pramipexole withdrawal and substitution with ropinirole (8 mg/day) [154] . … Outside PD, but within the broader dopaminergic-therapy context, antiandrogen therapy has been described as an adjunct when dopamine agonist cessation alone is insufficient: in a report on pramipexole-induced problematic sexual behaviors, oral medroxyprogesterone acetate (MPA) was used at 100 mg three …

Tumoral parkinsonism-Parkinsonism secondary to brain tumors, paraneoplastic syndromes, intracranial malformations, or oncological intervention, and the effect of dopaminergic treatment.

INTRODUCTION: Secondary tumoral parkinsonism is a rare phenomenon that develops as a direct or indirect result of brain neoplasms or related conditions. OBJECTIVES: The first objective was to explore to what extent brain neoplasms, cavernomas, cysts, paraneoplastic syndromes (PNSs), and oncological treatment methods cause parkinsonism. The second objective was to investigate the effect of dopaminergic therapy on the symptomatology in patients with tumoral parkinsonism. METHODS: A systematic literature review was conducted in the databases PubMed and Embase. Search terms like "secondary parki

Совпадение в полном тексте источника
… Levodopa–carbidopa 300 mg/d + pramipexole 1.05 (clear improvement, only micrographia remains) II.. Levodopa–carbidopa 1000 mg/day, safinamide added, pramipexole remains (good control, no fluctuation, no dyskinesia) III. Amantadine added for daytime sleepiness—partial effect IV. … Wimmer et al. wrote about a patient who was treated with levodopa and pramipexole for hemiparkinsonism associated with an arachnoid cyst. …

Topiramate as a rare cause of reversible Fanconi syndrome and acute kidney injury: a case report and literature review.

Cervical spine is affected in more than a half of patients with rheumatoid arthritis (RA). Depending on the degree of damage to the individual joints and ligaments RA-related cervical spine instability takes the form of atlanto-axial subluxation, subaxial subluxation or cranial settling. In the advanced cases spinal stenosis can occur as well as spinal cord injuries with typical neurological symptoms. The identification of patients with cervical spine instability before the occurrence of neurological complications still constitutes a diagnostic challenge. The article presents the methods of ce

Совпадение в полном тексте источника
… Her medications included aspirin 81 mg daily, pramipexole 0.5 mg at bedtime, albuterol inhaler as needed, buspirone 50 mg/day, risperidone 1 mg at bedtime, and topiramate (TPM) 100 mg twice a day for depression. …

Drug Repurposing for the Management of Depression: Where Do We Stand Currently?

A slow rate of new drug discovery and higher costs of new drug development attracted the attention of scientists and physicians for the repurposing and repositioning of old medications. Experimental studies and off-label use of drugs have helped drive data for further studies of approving these medications. A deeper understanding of the pathogenesis of depression encourages novel discoveries through drug repurposing and drug repositioning to treat depression. In addition to reducing neurotransmitters like epinephrine and serotonin, other mechanisms such as inflammation, insufficient blood supp

Совпадение в полном тексте источника
… Case reports also demonstrated that pramipexole, a relatively new dopamine receptor agonist, has potential effects in treating MDD. An observational study on 82,643 women revealed the relation between higher flavonoid intake and lower risk of MDD. … Brexpiprazole Phase III/2018 [ 35 ] | Experimental: brexpiprazole, 2–3 mg/day, once daily for 6 weeks, oral administration Placebo Comparator: placebo, 2–3 mg/day, once daily for 6 weeks, oral administration | 65/NA/NA MDD | R, PG, TB | NA | NA | NA Dopamine agonists Pramipexole Phase IV/2014 [ 47 , …

Синдром неспокойных ног: сетевая модель нейромодуляции железа-депендента-Нарративный обзор.

Синдром нервных ног (RLS) традиционно концептуализируется как сенсорное расстройство, реагирующее на допамин; однако новые данные говорят о более сложной и неоднородной нейробиологической основе. Результаты нейроимации, генетических исследований, циркадийской биологии и клинических исследований свидетельствуют о том, что допаминергическая дисфункция происходит в более широком контексте нейромодуляционного дисбаланса, включая метаболизм железа, аденозингергическую сигнализацию, глютаматергию и, возможно, норадренергические пути. Наряду с этим количественное картирование уязвимости и связанные с

Совпадение в полном тексте источника
… If used, doses should remain within conservative limits (pramipexole ≤ 0.5 mg; ropinirole ≤ 2.0 mg; rotigotine ≤ 3.0 mg daily). Intermittent low-dose levodopa or dopamine agonists may be appropriate for episodic symptoms (e.g., travel-related immobility). … Comparison of pregabalin with pramipexole for restless legs syndrome. N. Engl. J. Med. 2014;370:621–631. doi: 10.1056/NEJMoa1303646. 2. Manconi M., Garcia-Borreguero D., Schormair B., Videnovic A., Berger K., Ferri R., Dauvilliers Y. Restless legs syndrome. Nat. Rev. Dis. …

Нейропсихологические аспекты расстройств контроля импульсов в болезни Паркинсона.

Синдромы импульсного контроля (ИДД), такие, как чрезмерные азартные игры, навязчивое сексуальное поведение, поедание бингов, навязчивые покупки, а также синдром регулирования дофамина, могут возникать как изнурительное нервно-психическое осложнение болезни Паркинсона (PD). Хотя патофизиология не в полной мере понятна, она, вероятно, включает мезолимбичную допаминергическую чрезмерную оптимизацию в сочетании с факторами уязвимости, связанными с заболеваниями, в плане поощрения, мотивации и ингибиционных сетей контроля. В настоящем описательном обзоре резюмируются данные о нейропсихологических,

Совпадение в полном тексте источника
… Micheli et al. (2015) reported a patient on increasing doses of pramipexole who adopted cats but then felt an uncontrollable urge to kill them, while expressing distress and confusion about his actions. … This receptor selectivity contributes to ICD vulnerability, with pramipexole showing the highest association, followed by ropinirole, rotigotine, and pergolide. Apomorphine and bromocriptine are linked to lower risk ( Seeman, 2015 ). …

Ontology-based collection, representation and analysis of drug-associated neuropathy adverse events.

BackgroundNeuropathy often occurs following drug treatment such as chemotherapy. Severe instances of neuropathy can result in cessation of life-saving chemotherapy treatment.ResultsTo support data representation and analysis of drug-associated neuropathy adverse events (AEs), we developed the Ontology of Drug Neuropathy Adverse Events (ODNAE). ODNAE extends the Ontology of Adverse Events (OAE). Our combinatorial approach identified 215 US FDA-licensed small molecule drugs that induce signs and symptoms of various types of neuropathy. ODNAE imports related drugs from the Drug Ontology (DrON) wi

Совпадение в полном тексте источника
… antagonists of neuropathy-inducing drugs Target Agonists/antagonists Drugs adrenergic receptor agonists 3: Tizanidine, Salmeterol, Salmeterol xinafoate antagonists 7: Ziprasidone, Amiodarone, Amiodarone HCL, Propafenone, Betaxolol, Sotalol, Sotalol HCL dopamine agonists 4: Bromocriptine, Pergolide, Pramipexole … neuropathy-inducing drugs Target | Agonists/antagonists | Drugs adrenergic receptor | agonists | 3: Tizanidine, Salmeterol, Salmeterol xinafoate antagonists | 7: Ziprasidone, Amiodarone, Amiodarone HCL, Propafenone, Betaxolol, Sotalol, Sotalol HCL dopamine | agonists | 4: Bromocriptine, Pergolide, Pramipexole …

An approach to treating older adults with chronic kidney disease.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Consider dopamine agonists such as pramipexole (0.125–0.25 mg orally three times daily, as necessary) or ropinirole (starting dose 0.25 mg/d). 43 Depression | Manage contributing symptoms (e.g., pain, insomnia, pruritus). 43 Optimize social supports. …

The severity of corneal nerve loss differentiates motor subtypes in patients with Parkinson's disease.

BACKGROUND: Parkinson's disease (PD) is a heterogeneous movement disorder with patients manifesting with either tremor-dominant (TD) or postural instability and gait disturbance (PIGD) motor subtypes. Small nerve fiber damage occurs in patients with PD and may predict motor progression, but it is not known whether it differs between patients with different motor subtypes. OBJECTIVE: The aim of this study was to explore whether there was an association between the extent of corneal nerve loss and different motor subtypes. METHODS: Patients with PD classified as TD, PIGD, or mixed subtype unde

Совпадение в полном тексте источника
… Levodopa equivalent daily dose (LEDD) was assessed according to the levodopa conversion formula. 22 Briefly, 100 mg levodopa = 133 mg entacapone = 1 mg pramipexole = 5 mg ropinirole = 10 mg selegiline = 1 mg rasagiline = 100 mg amantadine. …

Abstracts - IANCON 2025

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Effects of Parkinson's disease on survival in cancer survivors: a retrospective, multicentre cohort study in Japan.

Aging populations and advances in medical care have contributed to an increase in the number of patients with Parkinson's disease and cancer survivors. However, the effects of Parkinson's disease on the survival of patients with cancer remain unclear. We aimed to investigate the effect of Parkinson's disease on the prognosis of patients with cancer. This retrospective multicentre cohort study used data from the Osaka Cancer Registry, which was linked to administrative data obtained between 2010 and 2015 in Japan. Patients with cancer who were followed up for 5 years after cancer diagnosis were

Совпадение в полном тексте источника
… For example, pramipexole extended-release (approved in 2011), ropinirole extended-release (approved in 2012), rotigotine patch (approved in 2013) and ropinirole patch (approved in 2019) enable continuous dopamine stimulation by dopamine agonists. …

Corneal confocal microscopy differentiates patients with Parkinson's disease with and without autonomic involvement.

Autonomic dysregulation in Parkinson's disease (PD) can precede motor deficits and is associated with reduced quality of life, disease progression, and increased mortality. Objective markers of autonomic involvement in PD are limited. Corneal confocal microscopy (CCM) is a rapid ophthalmic technique that can quantify small nerve damage in a range of peripheral and autonomic neuropathies. Here we investigated whether CCM can be used to assess autonomic symptoms in PD. Based on the scale for outcomes in Parkinson's disease for autonomic symptoms (SCOPA-AUT), patients with PD were classified into

Совпадение в полном тексте источника
… Briefly, 100 mg levodopa = 133 mg entacapone = 1 mg pramipexole = 5 mg ropinirole = 10 mg selegiline = 1 mg rasagiline = 100 mg amantadine. Autonomic symptom severity The SCOPA-AUT, a reliable and validated questionnaire that evaluates autonomic symptoms, was undertaken in patients with PD 44 . …

Окисляющий стресс и воспаление в патогенезе неврологических расстройств: механизмы и последствия.

Нейрозащита — это активный подход к защите нервной системы, включая мозг, спинной мозг и периферийные нервы, путем предотвращения или ограничения повреждения нервных клеток и других компонентов. Она защищает центральную нервную систему от повреждений от острых и прогрессивных нейродегенеративных расстройств. Окисляющий стресс, дисбаланс между естественными механизмами защиты тела и образованием реактивных видов кислорода, имеет решающее значение для развития неврологических расстройств. Из-за высокой скорости метаболизма и потребления кислорода мозг особенно уязвим к окисляющему стрессу. Чрезм

Совпадение в полном тексте источника
… Dopamine agonists like levodopa, pramipexole, and ropinirole mimic dopamine effects in PD to regulate motor symptoms. Cholinesterase inhibitors such as donepezil, rivastigmine, and galantamine slow the breakdown of acetylcholine, a crucial neurotransmitter for memory and cognition in AD. …

Corneal nerve fiber loss relates to cognitive impairment in patients with Parkinson's disease.

Cognitive impairment in Parkinson's disease (PD) adversely influences quality of life. There is currently no available biomarker to predict cognitive decline in PD. Corneal confocal microscopy (CCM) has been used as a non-invasive tool for quantifying small nerve damage in PD. The present study investigated whether corneal nerve measures were associated with cognitive function in PD. Patients with PD were classified into those with normal cognitive function (PD-CN), mild cognitive impairment (PD-MCI), and dementia (PDD). Corneal nerve fiber density (CNFD), corneal nerve branch density (CNBD),

Совпадение в полном тексте источника
… In brief, 100 mg levodopa = 133 mg entacapone = 1 mg pramipexole = 5 mg ropinirole = 10 mg selegiline = 1 mg rasagiline = 100 mg amantadine. …

Brigatinib и Alectinib for ALK Restruction-Positive Under-Spective Meta-Analysis с центральной нервной системой или без нее.

На сегодняшний день ни одно из испытаний не сравнивало эффективность бригатиниба и алектиниба с анапластической лимфатической киназой (АЛК) реструктуризацией положительной (ALK-p), АЛК-инбитор-наив, передовым раком легких немалых клеток (NSCLC) с метастазом центральной нервной системы (CNS). Мы провели непрямое сопоставление между бригатинибом и алектинибом с использованием кризотиниба в качестве общего компаратора, используя байезскую модель с неинформационным предварительным распределением, и провели оценку неоднородности исследований между исследованиями. Основным конечным показателем эффек

Совпадение в полном тексте источника
… Indirect comparison of ropinirole and pramipexole as levodopa adjunctive therapy in advanced Parkinson’s disease: A systematic review and network meta-analysis. Adv. Ther. 2019;36:1252–1265. doi: 10.1007/s12325-019-00938-1. 44. …

Chronic Kidney Disease: Strategies to Retard Progression.

Chronic kidney disease (CKD), defined as the presence of irreversible structural or functional kidney damages, increases the risk of poor outcomes due to its association with multiple complications, including altered mineral metabolism, anemia, metabolic acidosis, and increased cardiovascular events. The mainstay of treatments for CKD lies in the prevention of the development and progression of CKD as well as its complications. Due to the heterogeneous origins and the uncertainty in the pathogenesis of CKD, efficacious therapies for CKD remain challenging. In this review, we focus on the follo

Совпадение в полном тексте источника
… valve rupture, acute pericarditis, acute myocarditis Drugs exacerbate heart failure (COX inhibitors, CCB, TZD, DPP-4i) Drugs cause direct heart injury (rheumatologic agents (e.g., TNF-α inhibitors), anthracyclines, taxanes, targeted therapy (e.g., bevacizumab, sorafenib), anti-Parkinson (Pergolide, Pramipexole …

MicroRNA-7: a versatile player and core target in brain disorders.

OBJECTIVE: This article provides a systematic review of the biological characteristics, regulatory mechanisms, and roles of MicroRNA-7 (miR-7) in the nervous system, as well as explores its clinical translation potential and challenges. METHODS: A review analysis integrating the progress of basic and clinical research related to miR-7. RESULTS: Characteristics and Regulation: miR-7 is highly expressed in mammalian brain tissues, with its function finely regulated by ceRNA networks (such as ciRS-7 and lncRNA SNHG1) and epigenetic modifications, forming a multi-layer dynamic regulatory system.

Совпадение в полном тексте источника
… Additionally, pramipexole (a dopamine receptor agonist commonly used in PD treatment) can downregulate circSNCA expression, restoring miR-7-mediated inhibition of α-syn, thereby exerting a neuroprotective effect [ 46 ]. …

Fibromyalgia syndrome: etiology, pathogenesis, diagnosis, and treatment.

Fibromyalgia syndrome is mainly characterized by pain, fatigue, and sleep disruption. The etiology of fibromyalgia is still unclear: if central sensitization is considered to be the main mechanism involved, then many other factors, genetic, immunological, and hormonal, may play an important role. The diagnosis is typically clinical (there are no laboratory abnormalities) and the physician must concentrate on pain and on its features. Additional symptoms (e.g., Raynaud's phenomenon, irritable bowel disease, and heat and cold intolerance) can be associated with this condition. A careful differen

Совпадение в полном тексте источника
… The European League Against Rheumatism (EULAR) gave the highest level of recommendation of “A” to a set of pharmacological treatments (i.e., tramadol, amitriptyline, fluoxetine, duloxetine, milnacipran, moclobemide, pirlindol, tropisetron, pramipexole, and pregabalin), a recommendation strength of “B …